This $4 Stock Is About To Go Parabolic | SLS Stock Analysis скачать в хорошем качестве

This $4 Stock Is About To Go Parabolic | SLS Stock Analysis

SELLAS Life Sciences stock is trading near three dollars, but the setup behind SLS stock is anything but small. In this video, I break down why SELLAS Life Sciences could be dramatically undervalued ahead of its Phase 3 AML survival data and why the trial timeline itself may be quietly signaling success. SELLAS is developing galinpepimut S, a WT1 targeted cancer immunotherapy currently in a pivotal Phase 3 trial for acute myeloid leukemia. This is an event driven survival study that has now exceeded its original statistical assumptions, revised assumptions, and interim projections. In simple terms, the trial has taken far longer than expected because patients appear to be living much longer than modeled. I also cover SELLAS’ second pipeline asset, SLS009, a CDK9 inhibitor designed to enhance standard AML therapy and potentially address treatment resistance. Early clinical data has shown strong response rates, giving SELLAS exposure to both active disease treatment and post remission maintenance. This video explains -why the REGAL Phase 3 trial timeline matters -how GPS works and why WT1 is such a valuable cancer target -why SLS009 adds a second leg of upside -why SLS stock is still cheap despite late stage data and the real risks investors need to understand I am bullish on SLS stock and hold a large position, but this video is focused on fundamentals, trial design, and valuation math rather than hype. As always, this is not financial advice. Do your own research and understand the risks before investing. If you found this breakdown helpful, consider liking the video and subscribing for more deep dive stock analysis.